Biocon executive chairperson Kiran Mazumdar-Shaw tests COVID-19 positive
Biocon's Kiran Mazumdar Shaw tweeted stating, "I have added to the Covid count by testing positive..."
- FB
- TW
- Linkdin
 "<p>Executive chairperson of Bengaluru-headquartered Biocon Ltd Kiran Mazumdar-Shaw tested positive for coronavirus on August 17. </p>")
<p>Executive chairperson of Bengaluru-headquartered Biocon Ltd Kiran Mazumdar-Shaw tested positive for coronavirus on August 17. </p>
Executive chairperson of Bengaluru-headquartered Biocon Ltd Kiran Mazumdar-Shaw tested positive for coronavirus on August 17.
<p>She took to Twitter to announce the news stating, "I have added to the covid count by testing positive. Mild symptoms and I hope it stays that way."</p>
She took to Twitter to announce the news stating, "I have added to the covid count by testing positive. Mild symptoms and I hope it stays that way."
<p><br /> The 67-year-old biotechnology industry veteran received hundreds of get-well-soon messages after she posted the tweet.<br /> </p>
The 67-year-old biotechnology industry veteran received hundreds of get-well-soon messages after she posted the tweet.
<p><br /> In the state, chief minister BS Yediyurappa, Leader of Opposition Siddaramaiah and state Health Minister B Sriramulu have recovered from COVID-19.</p>
In the state, chief minister BS Yediyurappa, Leader of Opposition Siddaramaiah and state Health Minister B Sriramulu have recovered from COVID-19.
<p><br /> According to reports, Bengaluru Urban district has the biggest number of coronavirus cases in Karnataka with over 91,000 cases.</p>
According to reports, Bengaluru Urban district has the biggest number of coronavirus cases in Karnataka with over 91,000 cases.
<p><br /> </p> <p>Biocon is one of the companies looking to develop a vaccine to fight COVID-19. In July, regulator the Drug Controller General of India (DCGI) allowed it to market a repurposed injection, Itolizumab, which was originally launched in 2013 for treating chronic plaque psoriasis.</p>
Biocon is one of the companies looking to develop a vaccine to fight COVID-19. In July, regulator the Drug Controller General of India (DCGI) allowed it to market a repurposed injection, Itolizumab, which was originally launched in 2013 for treating chronic plaque psoriasis.
